Viewing Study NCT03723720


Ignite Creation Date: 2025-12-25 @ 4:16 AM
Ignite Modification Date: 2026-01-28 @ 7:42 PM
Study NCT ID: NCT03723720
Status: COMPLETED
Last Update Posted: 2023-03-02
First Post: 2018-10-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Calculating of Correlations Between ADR, PDR, MAP
Sponsor: Hospital Frydek-Mistek
Organization:

Study Overview

Official Title: Calculating of Correlations Between ADR, PDR, MAP
Status: COMPLETED
Status Verified Date: 2023-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of our study is to compare MAP (mean adenoma per colonoscopy) with ADR (adenoma detection rate) and PDR (polyp detection rate) of all colonoscopists in our department
Detailed Description: ADR (adenoma detection rate) is generally accepted quality indicator. For possible gaming with ADR other indicators are needed. MAP (mean adenoma per colonoscopy) reflects the quality of examination of entire colon and is considered to be the most objective quality indicator. The aim of our study is to compare MAP with ADR and PDR (polyp detection rate) of all colonoscopists in our department.

We want to retrospectively assess the quality indicators of all colonoscopies from January 2013 to December 2017. We want to calculate ADR, PDR and MAP of all our endoscopists for all colonoscopies in patients over 50 years of age excluding therapeutic, IBD, management of complications and sigmoidoscopies (screening, surveillance, diagnostic) and separately only for screening colonoscopies. Correlations between MAP/ADR and MAP/PDR will be performed using Pearson“s correlation coefficient.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: